Investment analysis, share recommendations, and market insights.
Playing Donald Trump’s tariffs involves calculating the risk of just how serious a trade war might become. Here are a few ways to play the tariff world of 2025 and beyond.
Led by a buoyant Wall Street, the Australian share market hit a record high at the end of January. Our model portfolios followed suit and recorded solid gains for the month. In this article, we look at how they have performed so far in 2025.
In our “HOT STOCK” column today, Raymond Chan, Head of Asian Desk at Morgan’s explains why he regards ResMed (RMD) as an ADD to an investor’s portfolio.
Is there value in the S&P/ASX 20 right now? Here’s a look at four ‘buy’ prospects from the ASX’s top echelon: Telstra, Rio Tinto, BHP and CSL.
While it’s hard to identify stocks I want to buy in this ‘expensive’ market, here are two suggestions, for different reasons and different objectives – yield and growth.
Always looking for sensible contrarian investments, Toney Featherstone pinpoints two ways to get exposure to data centres, office, retail and other assets, at a time when falling interest rates and pressure for workers to go back to the office might be game changing pluses for this sectors’ stocks.
In our “HOT” stock article today, Michael Gable, MD of Fairmont Equities, explains why any breakout from its current base could lead to a significant multi-month move in Magellan Financial (MFG).
In our second “HOT” stock article today, Raymond Chan, Head of Asian Desk at Morgans explains why he regards Megaport (MP1) as an ADD to an investor’s portfolio.
Here are two Australian medical device companies doing impressive things in the medical imaging area in Australia and the US.
After the US stock market delivering big time for two years, the big question is, should long-term investors at least do a partial rotation into European or Japanese stocks via quality ETFs?
You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.